Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel(Chinese University of Hong Kong), Rury R. Holman(University of Oxford), Rishi Patel(University of Oxford), John B. Buse(Unknown), Robert J. Mentz(Duke University), Neil R Poulter(Imperial College London), Stephanie M. Gustavson(Chinese University of Hong Kong), Aldo P. Maggioni(Health Care Foundation), Neha J. Pagidipati(Duke University), Bernard Zinman(Mount Sinai Hospital), Juliana C.N. Chan(Chinese University of Hong Kong), Yuliya Lokhnygina(Clinical Research Institute), Nayyar Iqbal(Chinese University of Hong Kong), Peter Merrill(Duke University), Ambady Ramachandran(M.V. Hospital for Diabetes and Diabetes Research Centre), Peter Öhman(Chinese University of Hong Kong), Adrian F. Hernandez(Duke University)
Cited by 591
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k